SecBot SecBot
8-K ·Filed Feb 26, 2026

ONC

BeOne Medicines Ltd.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago SEC0001628280-26-011941
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong revenue growth and raised guidance suggest continued momentum in BRUKINSA's global expansion. Traders should monitor upcoming regulatory milestones for Sonrotoclax and TEVIMBRA, which could provide additional catalysts. The significant improvement in profitability and cash flow generation indicates strong operating leverage.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$322.37
T+0 close · Feb 26, 2026 · via day close
Latest settled
−3.96%
T+60 · $309.62
Vs SPY
−11.71%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $322.37entry
  2. T+1 · 9mo ago −1.67%α −1.22% · $316.99
  3. T+5 · 9mo ago −9.13%α −8.00% · $292.94
  4. T+20 · 8mo ago −14.09%α −7.69% · $276.95
  5. T+60 · 6mo ago −3.96%α −11.71% · $309.62
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BeOne Medicines reported strong Q4 and full-year 2025 financial results, with total global revenues of $1.5 billion and $5.3 billion, representing 33% and 40% year-over-year growth, respectively. Diluted GAAP earnings per ADS were $0.58 for Q4 and $2.53 for the full year. The company raised its full-year 2026 revenue guidance to $6.2-$6.4 billion, driven by BRUKINSA's global leadership and continued expansion.

Key Financial Metrics

Revenue
$5.3B
+40.0% YoY
Adj. EPS
$8.09
GAAP: $2.53
Guidance
$6.2 - $6.4 billion
raised
Free Cash Flow
$941.7M
Gross Margin
87.3%

Key Facts

  • Total global revenues of $1.5 billion for Q4 2025, up 33% YoY
  • Total global revenues of $5.3 billion for full year 2025, up 40% YoY
  • Diluted GAAP EPS of $0.58 for Q4 2025 and $2.53 for full year 2025
  • Full year 2026 revenue guidance of $6.2-$6.4 billion
  • BRUKINSA global sales of $1.1 billion in Q4 2025, up 38% YoY
  • Free cash flow of $941.7 million for full year 2025

Financial Impact

Revenue growth of 33-40% YoY, with 2026 guidance of $6.2-$6.4 billion

revenueepsguidancefreeCashFlow

Segment Breakdown

SegmentRevenueGrowth
BRUKINSA$3.9B+49.0%
TEVIMBRA$737.0M+19.0%
Amgen in-licensed products$486.0M+33.0%

Risk Factors

  • Forward-looking statements about 2026 guidance are subject to significant uncertainties
  • Dependence on continued success and market acceptance of BRUKINSA
  • Potential regulatory delays for new drug approvals

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-011941
Document: bgne-20260226.htm0001628280-26-011941
Document: 0001628280-26-011941-index-headers.html0001628280-26-011941
Document: 0001628280-26-011941-index.html0001628280-26-011941
Document: 0001628280-26-011941.txt0001628280-26-011941
CONTEXT: Previous Earnings (2026-02-26)0001628280-26-011941

Track record

27 reports on ONC

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +12.55% at T+60 after the Aug 5, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $416.54 Now $411.29 −1.26% settles Nov 23
  2. Nov 10, 20266d ago Insider Cluster Neutral 3/10 Entry $419.98 Now $411.29 −2.07% settles Nov 18
  3. Nov 6, 202610d ago 144 Neutral 2/10 Entry $417.33 to $411.29 Now $411.29 −1.45% ▼ −1.45% +0.25% vs SPY
  4. Nov 5, 202611d ago 144 Neutral 2/10 Entry $406.96 to $416.54 Now $411.29 +1.06% ▲ +2.35% −0.24% vs SPY
  5. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $387.25 to $415.96 Now $411.29 +6.21% ▲ +7.41% +4.12% vs SPY
  6. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $377.78 to $419.98 Now $411.29 +8.87% ▲ +11.17% +12.08% vs SPY
  7. Oct 2, 20266w ago Insider Cluster Bearish 5/10 Entry $361.65 to $350.40 Now $411.29 −13.73% ▲ +3.11% +3.53% vs SPY
  8. Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $368.08 to $365.27 Now $411.29 +11.74% ▼ −0.76% +0.42% vs SPY
  9. Sep 10, 20269w ago Insider Cluster Neutral 3/10 Entry $346.51 to $350.84 Now $411.29 +18.69% ▲ +1.25% +1.47% vs SPY
  10. Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $358.26 to $353.83 Now $411.29 +14.80% ▼ −1.24% −0.03% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens in 9h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026